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tNTRODUCTION
Mesenchymal stromal cells (MSCs) are the spindle-
haped plastic-adherent cells isolated from BM, adi-
ose, and other tissue sources, with multipotent dif-
erentiation capacity in vitro. However, whether
SCs truly qualify as stem cells is an area of some
ebate [1]. MSCs were ﬁrst described by Frienden-
tein et al [2,3] as hematopoietic supportive cells of
M. They showed that MSCs could differentiate to
one in vitro and a subset of the cells had a high
roliferative potential (CFU-F) when plated at low
ensity in tissue culture [2,3]. Based largely on their
ork, Owen and Friedenstein [4] proposed the existence
f a stromal stem cell to maintain the marrow microen-
ironment as the HSC maintains hematopoiesis. The
otion of a mesenchymal stem cell was popularized by
aplan [5] who proposed that MSCs gave rise to bone,
artilage, tendon, ligament, marrow stroma, adipocytes,
ermis, muscle, and connective tissue. However, con-
incing data to support the “stemness” of these cells were
ot forthcoming, and currently most investigators rec-
gnize that in vitro isolatedMSCs are not a homogenous
opulation of stem cells, although a bona ﬁde mesen-
hymal stem cell may reside within the adherent cell
ompartment of marrow [6].
MSCs undoubtedly play a critical role in the marrow
icroenvironment. After intramedullary transplantation
f eGFP-marked human MSCs into a NOD SCID
ouse, the MSCs incorporated into the murine marrow
icroenvironment and improved the human HSC ac-
ivity in the host mouse [7]. MSCs are also thought to be
f great value for cell-based therapies. This discussion
ocuses on the properties of MSCs that engender their
tility as therapeutic cells and speciﬁcally on MSCs as
reatment for GVHD and as targeting vehicles for anti-
umor therapies. MOMENCLATURE
Data to support the designation of MSCs as bio-
ogically functional stem cells are lacking. However,
he acronym MSC is ﬁrmly ingrained in the vernac-
lar of cell biologists and clinical cell therapists. Thus,
he International Society for Cellular Therapy has
ecommended that these spindle-shaped, plastic-ad-
erent cells be termed “mesenchymal stromal cells”
6]. This label allows investigators to continue to use
he acronym MSCs, which should reduce the potential
or confusion in the literature. A biologically active
tem cell for mesenchymal tissues may exist, but the
erm “mesenchymal stem cell” should be reserved for
he subset of mesenchymal cells that demonstrate
tem cell activity by rigorous criteria.
HENOTYPE
The deﬁning characteristics of MSCs are incon-
istent among investigators due in part to the lack of a
niversally accepted surface marker phenotype. How-
ver, all proposed MSC populations are plastic adher-
nt in vitro; hence, this is a deﬁning characteristic.
he ﬁrst important studies of surface antigen markers
ed to the development of SH2 and SH3, antibodies,
hich seemed to identify MSCs [8]. Subsequently,
H2 and SH3 were shown to recognize epitopes on
D105 and CD73, respectively [9,10]. Further, CD90
s expressed on all cells that we accept as MSCs. These
ells do not express hematopoietic antigens, eg,
D45, CD34, CD14, CD19, or CD3. In addition,
SCs express MHC class I molecules in vitro, but not
lass II molecules unless stimulated, eg, by IFN, in
issue culture. Thus, a surface marker phenotype of
SCs is CD105, CD73, CD90, CD45, CD34,
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E. M. Horwitz et al.54D14, CD19, CD3, and HLA-DR. Although
nequivocally identifying MSCs, this surface marker
roﬁle is cumbersome. Stable, pancellular expression
f surface markers that are unique to MSCs within the
M, the most common source of MSCs, would greatly
acilitate the identiﬁcation of these cells.
The single most characteristic feature of MSCs is
he capacity to differentiate to osteoblasts, adipocytes,
nd chondroblasts in vitro. It is therefore quite rea-
onable for investigators to demonstrate such trilin-
age differentiation in vitro to prove their cells under
tudy are MSCs.
In practice, MSCs can be deﬁned by the criteria
isted in Table 1, as proposed by the International
ociety for Cellular Therapy Mesenchymal and Tis-
ue Stem Cell Committee [11]. The criteria are de-
igned not only to deﬁne the MSCs but also to exclude
ematopoietic cells, which is important because MSCs
re most commonly isolated from BM. CD3 expres-
ion is not included in the criteria because T cells are
ncommon contaminants of MSC preparations. It is
mportant to avoid hematopoietic cells among the
opulations of MSCs being used for cell therapy stud-
es because they could alter the scientiﬁc outcomes
nd may be deleterious for patients in clinical trials.
SOLATION OF MSCS
For obvious reasons, if the proposed therapeutic
ells are not readily accessible, clinical utility is lim-
ted. Effective cell therapy, therefore, begins with a
ell type that is relatively easy to isolate. MSCs are
ost often isolated by “adherence selection.” For ex-
mple, BM mononuclear cells are placed in a plastic
issue culture vessel and maintained for 1-5 d at 37°C.
hen the nonadherent cells are removed as the me-
ium is changed and the remaining adherent cells are
solated MSCs. At this stage, the MSC cultures are
eﬁnitely not free of contamination by resident tissue
ells, eg, hematopoietic cells; however, successive pas-
ages of the ex vivo expanded cells effectively remove
ost or all contaminating cells. Thus, tissue culture
erves to expand and purify the MSCs. Similarly,
able 1. Summary of Criteria to Identify Mesenchymal Stromal Cells
Adherence to Plastic in Standard Culture Conditions
Phenotype Positive (>95% ) Negative (<2% )
CD105 CD45
CD73 CD34
CD90 CD14 or CD11b
CD79 or CD19
HLA-DR
ifferentiation Bone, adipose, cartilage (by staining of in
vitro cell culture)hen using other sources of MSCs, eg, adipose tissue, tmononuclear cell preparation is maintained in tissue
ulture to isolate the MSCs.
SCS AS CELL THERAPY FOR TISSUE REGENERATION
There are 3 fundamental questions that must be
ddressed when using MSCs as cell therapy for tissue
egeneration. First, will MSCs differentiate to the
issue of interest in vivo? This is a critically important
ssue because certain culture conditions may induce
typical differentiation in vitro that may not occur in
ivo. In addition, MSCs may not differentiate to the
argeted tissue, but instead generate cell types that
unction in a beneﬁcial way within the tissue. For
xample MSCs may secrete useful soluble mediators
hat foster repair of a tissue so that differentiation is
nneeded for clinical beneﬁt. Thus, MSCs may be
ighly effective for applications in regenerative med-
cine by several mechanisms.
Second, how can the cells be delivered to the
elevant tissue(s)? For example, if infused i.v., will
SCs home to the desired sites? Although some in-
estigators have suggested that MSCs home to sites of
nﬂammation, it is unclear that MSCs home to sites of
ther types of local or systemic disease, and there are
ew data indicating that MSCs home to healthy tissue.
espite the uncertainty of homing to diseased tissues,
ufﬁcient i.v. infused MSCs may arrive and incorpo-
ate in the desired tissue to generate clinical beneﬁts.
or example, Horwitz et al [12] reported the infusion
f MSCs after BMT into children with osteogenesis
mperfecta, a metabolic bone disorder. Engraftment
nd growth acceleration was demonstrated in 5 of 6
atients. Koc et al [13] described MSC infusion in
hildren with metachromatic leukodystrophy and
urler disease after BMT. In 4 of 6 patients with
etachromatic leukodystrophy, an improvement in
erve conduction velocity was observed, but engraft-
ent in the neural tissue was not assessed. In both
ases, homing strictly deﬁned was not demonstrated;
owever, the former study showed the presence of i.v.
nfused cells within the targeted tissue.
Third, how much tissue replacement by donor
ells (ie, engraftment) is needed to achieve correction
r improvement of the damage or diseased tissue? The
nswer will likely be tissue and disease speciﬁc and
herefore will require animal models that reliably
odel the human disease, or more effectively, pilot
linical trials. Importantly, the level of tissue replace-
ent is often quite low, far less than what may be
ypothesized; in consequence, estimates are useful to
etermine which diseases should be investigated, but
xperimental data are essential to formulate therapeu-
ic strategies.
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Mesenchymal Stromal Cells 55MMUNOLOGIC PROPERTIES OF MSCS
Any cell employed for therapeutic purposes would
deally be immunoprivileged, allowing for use in
LA-mismatched patients. Further, cells that can
egulate the immune response could be effectively
sed to modulate the immune system to treat immu-
ologic disease. MSCs have been reported to be im-
unosuppressive and immunoprivileged. The 2 terms
re often used interchangeably; however, this is
trictly incorrect. A cell may escape immune recogni-
ion (ie, immunoprivileged) without having an effect
n immune effector cells. Similarly, a cell may secrete
mmunosuppressive molecules and be recognized by
n allogeneic immune system. MSCs do seem to ex-
ibit an effect on the immune effector cells in vitro.
his property has led to much dialogue about whether
SCs could be effective therapy for autoimmune dis-
ases such as rheumatoid arthritis. More important for
his discussion is the role of MSCs in the treatment of
VHD.
SCS FOR TREATMENT OF GVHD
MSCs are an essential component of the stromal
caffold of the BM that provides physical and func-
ional support during hematopoiesis. Based on this
oncept, MSCs have been studied for their ability to
mprove engraftment of HSCs in vivo [14,15]. Al-
hough some reports have suggested that MSCs in-
rease engraftment, the data are not particularly im-
ressive, at least in the models used. It has been
ecently shown that MSCs exert a profound immuno-
odulatory effect by means of soluble and cell con-
act-dependent mechanisms [16]. MSCs can act on T
nd B cells and, although several mechanisms of action
ave been suggested, the data are contradictory. The
bility to inhibit or stimulate T cell allogeneic re-
ponses appears to be independent of HLA matching.
t is still unclear whether MSCs naturally exhibit an
mmunoregulatory role or whether this is the conse-
uence of a more general, nonspeciﬁc interference
ith the cell cycle [17].
In this context, it is interesting to note that stro-
al cells, in addition to osteoblasts and endothelial
ells, contribute to the formation of the HSC niche.
his can be deﬁned as a specialized microenvironment
hat precisely maintains a long-term storage of quies-
ent, slowly dividing HSCs by preventing their pro-
iferation, differentiation, or apoptosis. It can be
ypothesized that MSCs, on the one hand, are pre-
enting T lymphocyte activation and proliferation (to
revent possible harm on HSCs) and, on the other
and, seem to exert a potent antiapoptotic effect.
lthough the mechanisms of immunomodulation
re still unfolding, a relevant in vivo immunomodu-
atory effect has been shown: (a) if given in patients tith severe aGVHD, they are able to reverse the
volution of GVHD in a signiﬁcant proportion of
atients [18,19], and (b) in a recent in vivo experi-
ent in which injection of MSCs ameliorated the
ourse of chronic progressive experimental autoim-
une encephalomyelitis, the mouse model of mul-
iple sclerosis [20].
The European Group for Blood and Marrow
ransplantation (EBMT) MSC Expansion Consor-
ium used MSCs to treat grade III-IV GVHD in 40
atients who were resistant to second-line GVHD
reatment. The MSC dose was a median 1.0  106
ells/kg recipient body weight (range, 0.4-9  106
ells/kg). Adverse effects were not seen after MSC
nfusions. Nineteen patients received 1 dose, 19 pa-
ients received 2 doses, 1 patient received 3 doses, and
patient received 5 doses. In some cases, an individual
atient received MSC doses from different donors.
he MSC donors were HLA-identical siblings in
cases, haploidentical donors in 19 cases, and third-
arty HLA-mismatched donors in 41 cases. Among
he 40 patients treated for severe aGVHD, 19 had
omplete responses, 9 showed improvement, 7 did
ot respond, 4 had stable disease, and 1 was not
valuated due to short follow-up. Ectopic tissue for-
ation was not seen. MSC dramatically affected tissue
epair of severe aGVHD of the gut, liver, and skin in
consistent proportion of patients. Twenty-one pa-
ients were alive at 6-wk to 3.5-yr follow-up after
ransplantation. Nine of these patients had extensive
GVHD. One patient with ALL had recurrent leuke-
ia and 1 patient had de novo AML of host origin. In
iew of the dismal outcome in patients with grade
II-IV aGVHD, the data from this small trial are
romising. However, the optimal strategy for the
reatment of GVHD based on MSC infusion has not
et been determined and remains rather complex for a
everal reasons: (a) ex vivo cell expansion is expensive
nd time consuming; (b) there is variation in the ex-
ansion capability from donor to donor; (c) often,
reviously expanded MSCs are required for the timely
reatment of GVHD; (d) the optimal dose of MSCs,
r the need for multiple infusions, to obtain the max-
mal effect on GVHD is unknown; and (e) expanded
SCs are very difﬁcult to detect after infusion, and
atients’ marrow stroma remain of host origin with
he possible exception of some pediatric patients.
Ongoing efforts within the EBMT consortium
re addressing these challenges in an effort to de-
ermine the role of MSC therapy in the treatment
or GVHD. At the current state of research, we
onclude that MSCs have immunomodulatory and
issue-repairing effects and should be further ex-
lored as treatment of severe aGVHD in prospec-
ive randomized trials.
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E. M. Horwitz et al.56SCS AS TUMOR-TARGETING DRUG DELIVERY
YSTEMS
The formation of stroma is essential for tumor
rowth and involves complex interactions between
alignant tumor cells and non-tumor stromal cells.
tudeny and others [21-23] demonstrated that
SCs integrate into solid tumors, suggesting the
evelopment of anticancer therapies based on the
ntratumoral production of agents by gene-modiﬁed
SCs.
Andreeff and colleagues have conducted a series of
xperiments to address this issue by noninvasively vi-
ualizing MSCs using luciferase bioluminescence. The
ells were labeled by a ﬁber-modiﬁed adenoviral vec-
or expressing ﬁreﬂy luciferase (AdLux-F/RGD) and
he MSC-Lux was injected into normal (healthy)
CID mice or mice bearing established metastatic
reast or ovarian tumors. Biodistributed MSC-Lux
as imaged using the Xenogen IVIS detection system.
n normal mice, human MSCs (hMSCs) migrated to
he lungs, where they remained resident for 7-10 d. In
nimals bearing established metastatic lung tumors,
.v. injected hMSCs again migrated to the lungs.
owever, in contrast to control mice, the Lux signal
emained strong over a 15-d period, with only a slight
ecrease over the ﬁrst 10 d. After i.p. injection,
MSC-Lux was detected in the peritoneum, and after
d no hMSC-Lux was detected in normal animals,
hereas strong punctate regions of Lux activity was
bserved in ovarian tumors. In contrast to SCID mice
njected with hMSCs, when healthy Balb/C mice were
njected, Balb/C-derived MSC-Lux initially migrated
o the lungs, but within 2.5 h had exited the lungs to
emain in the liver and spleen for 5-7 d. Tumor cells
ere then transduced with renilla luciferase constructs
llowing for the colocalization and dynamic interac-
ions of ﬁreﬂy luciferase MSCs and renilla luciferase
umors to be demonstrated.
Human MSC-producing IFN  MSCs (IFNb-
SCs) were found to inhibit the growth of metastatic
umors in the lungs of SCID mice. When injected i.v.
4 doses of 106 MSCs/wk) into SCID mice bearing
ulmonary metastases of carcinomas or melanomas,
umor growth was signiﬁcantly inhibited compared
ith untreated or vector-control MSC controls (P 
007), whereas recombinant IFNb protein (50 000 IU
.o.d.) was ineffective (P  0.14). Intravenously in-
ected IFNb-MSCs prolonged the survival of mice
earing metastatic breast carcinomas (P  .001). In-
raperitoneal injections of IFN-MSCs into mice car-
ying ovarian carcinomas resulted in doubling of sur-
ival in SKOV-3 and cures in 70% of mice carrying
VAR-3 tumors.
A similar strategy is also effective as therapy for
rain tumors. MSCs injected into the ipsilateral or
ontralateral carotid artery were found to localize tolioma xenografts in mice and IFNb-MSCs signiﬁ-
antly (P  .05) prolonged survival of these mice [24].
These data suggest that systemically administered
ene-modiﬁed MSCs selectively engraft into the tu-
or microenvironment and remain resident as part of
he tumor architecture. IFNb-MSCs inhibit the
rowth of melanomas, gliomas, metastatic breast, and
varian cancers in vivo and prolong the survival of
ice bearing established tumors. Thus, MSCs are
otentially a universal vehicle to deliver localized an-
itumor therapy. Clinical trials, which are in develop-
ent, will be conducted to test these experimental
ndings.
ONCLUSIONS
MSCs have an enormous potential as cell therapy
n tissue regeneration, immune modulation, and de-
ivery vehicles for the speciﬁc delivery vehicles for
ntitumor agents, but the true clinical utility remains
o be proved. MSCs are relatively easy to isolate and
urify, and we currently have means to unequivocally
dentify the cells, although more speciﬁc surface
arkers are needed. MSCs have been infused into
100 patients, including young children, without se-
ious adverse events, thus testifying to the general
afety of this strategy. Future efforts in our ﬁeld must
ocus on better deﬁning the therapeutic potential of
SCs through clinical trials and better understanding
f the biology of MSCs to elucidate the mechanisms
f these therapeutic effects.
EFERENCES
1. Horwitz EM, Keating A. Nonhematopoietic mesenchymal
stem cells: what are they? Cytotherapy. 2000;2:387-388.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP.
Heterotopic of bone marrow. Analysis of precursor cells for
osteogenic and hematopoietic tissues. Transplantation. 1968;6:
230-247.
3. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precur-
sors for ﬁbroblasts in different populations of hematopoietic
cells as detected by the in vitro colony assay method. Exp
Hematol. 1974;2:83-92.
4. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived
osteogenic precursors. Ciba Found Symp. 1988;136:42-60.
5. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641-
650.
6. Horwitz E, Le Blanc K, Dominici M, et al. Clariﬁcation of the
nomenclature for MSC: the International Society for Cellular
Therapy position statement. Cytotherapy. 2005;7:393-395.
7. Muguruma Y, Yahata T, Miyatake H, et al. Reconstitution of
the functional human hematopoietic microenvironment derived
from human mesenchymal stem cells in the murine bone mar-
row compartment. Blood. 2006;107:1878-1887.
8. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage po-
tential of adult human mesenchymal stem cells. Science. 1999;
284:143-147.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
Mesenchymal Stromal Cells 579. Barry FP, Boynton RE, Haynesworth S, Murphy JM, Zaia J.
The monoclonal antibody SH-2, raised against human mesen-
chymal stem cells, recognizes an epitope on endoglin (CD105).
Biochem Biophys Res Commun. 1999;265:134-139.
0. Barry F, Boynton R, Murphy M, Zaia J. The SH-3 and SH-4
antibodies recognize distinct epitopes on CD73 from human
mesenchymal stem cells. Biochem Biophys Res Commun. 2001;
289:519-524.
1. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for
deﬁning multipotent mesenchymal stromal cells. The Interna-
tional Society for Cellular Therapy position statement. Cyto-
therapy. 2006;8:315-317.
2. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allo-
geneic bone marrow-derived mesenchymal cells engraft and
stimulate growth in children with osteogenesis imperfecta:
implications for cell therapy of bone. Proc Natl Acad Sci USA.
99, 8932-8937.
3. Koc ON, Day J, Nieder M, et al. Allogeneic mesenchymal stem
cell infusion for treatment of metachromatic leukodystrophy
(MLD) and Hurler syndrome (MPS-IH). Bone Marrow Trans-
plant. 2002;30:215-222.
4. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic
recovery after coinfusion of autologous-blood stem cells and
culture-expanded marrow mesenchymal stem cells in advanced
breast cancer patients receiving high-dose chemotherapy. J Clin
Oncol. 2000;18:307-316.
5. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of
HLA-identical sibling culture-expanded mesenchymal stem
cells and hematopoietic stem cells in hematologic malignancy
patients. Biol Blood Marrow Transplant. 2005;11:389-398.6. Le Blanc K, Ringden O. Immunobiology of human mesenchy-
mal stem cells and future use in hematopoietic stem cell trans-
plantation. Biol Blood Marrow Transplant. 2005;11:321-334.
7. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone
marrow mesenchymal stem cells induce division arrest anergy
of activated T cells. Blood. 2005;105:2821-2827.
8. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem
cells for treatment of therapy-resistant graft-versus-host dis-
ease. Transplantation. 2006;81:1390-1397.
9. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe
acute graft-versus-host disease with third party haploidentical
mesenchymal stem cells. Lancet. 2004;363:1439-1441.
0. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem
cells ameliorate experimental autoimmune encephalomyelitis
inducing T-cell anergy. Blood. 2005;106:1755-1761.
1. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ,
Andreeff M: Bone marrow-derived mesenchymal stem cells as
vehicles for interferon-beta delivery into tumors. Cancer Res.
2002;62:3603-3608.
2. Studeny M, Marini FC, Dembinski JL, et al, Mesenchymal
stem cells: potential precursors for tumor stroma and targeted
delivery vehicles of anti-cancer agents. J Natl Cancer Inst. 2004;
96:1593-1603.
3. Marini F, Hall B, Dembinski J, et al. Mesenchymal stem cells as
vehicles for genetic targeting of tumors. In: Ho AD, Hoffman
R, Zanjani ED, eds. Stem Cell Transplantation. Weinheim, Ger-
many: Wiley-VCH Verlag; 2006:157-175.
4. Nakamizo A, Marini F, Studeny M, et al. Human bone mar-
row-derived mesenchymal stem cells in the treatment of glio-
mas. Cancer Res. 2005;65:3307-3318.
